title: Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment.
abstract: OBJECTIVE
  The recommended treatment for chronic hepatitis C is a combination of pegylated interferon (PEG IFN) plus ribavirin (RBV). However, the sustained virological response (SVR) rate of PEG IFN-RBV therapy was approximately 50% in patients with genotype 1b and a high viral load. Thus, we compared the efficiencies and side-effects of PEG IFN-RBV and self-injected low-dose natural (n) IFN-α in patients with hepatitis C virus (HCV).
  
  
  METHODS
  A prospective, multicenter, open-label study was conducted in 12 Japanese institutions. A total of 129 patients with chronic hepatitis C and no detectable HCV after 24-72 weeks of PEG IFN-RBV treatment were assigned to the control (n = 82) or treated (n = 47) group. Treated patients received 3 million units of nIFN-α 2-3 times/week over 96 weeks. The groups were compared regarding treatment efficiency and side-effects.
  
  
  RESULTS
  Significant treatment success regarding virus negativation rates was found, with 89% and 73% for the treated and control groups, respectively (P = 0.039). In contrast, there was no difference in relapse rate between the groups 24 weeks after the 96-week nIFN-α treatment (P = 0.349). However, when early viral responders and late viral responders (LVR) were separated, LVR patients responded significantly to the treatment with 90% sustained virological response, compared to 53% for the control group (P = 0.044). The side-effects of nIFN-α were less than that of PEG IFN-RBV treatment.
  
  
  CONCLUSIONS
  Self-injected nIFN-α has larger benefits than prolonged PEG IFN-RBV for chronic hepatitis C patients with high viral loads of genotype 1b who fail to achieve early viral response during initial combination treatment.
authors: Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College Of Medicine, Japan.
authors: Tomoyuki
authors: T
authors: Takashima
authors: Hirayuki
authors: H
authors: Enomoto
authors: Toshiaki
authors: T
authors: Ninomiya
authors: Soo Ryang
authors: SR
authors: Kim
authors: Hiroaki
authors: H
authors: Okushin
authors: Masahiko
authors: M
authors: Sugano
authors: Susumu
authors: S
authors: Imoto
authors: Yoshihiko
authors: Y
authors: Yano
authors: Teruji
authors: T
authors: Ooka
authors: Yasushi
authors: Y
authors: Seo
authors: Hiroshi
authors: H
authors: Kasugai
authors: Akira
authors: A
authors: Muramatsu
authors: Hisato
authors: H
authors: Jomura
authors: Soji
authors: S
authors: Shimomura
authors: Michiko
authors: M
authors: Shindo
authors: Hideji
authors: H
authors: Nakamura
authors: Nobuhiro
authors: N
authors: Aizawa
authors: Yoshinori
authors: Y
authors: Iwata
authors: Masaki
authors: M
authors: Saito
authors: Hiroyasu
authors: H
authors: Imanishi
authors: Hiroko
authors: H
authors: Iijma
authors: Shuhei
authors: S
authors: Nishiguchi
keywords: chronic hepatitis C; hepatitis C virus; interferon-α; pegylated interferon